NOC2 like nucleolar associated transcriptional repressor pseudogene 2Genealiases: []
Q-omics provides the consensus-scored NOC2LP2 profile across patient tissues and cancer cell-line models. NOC2LP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NOC2LP2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NOC2LP2 RNA expression shows 14,570 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where NOC2LP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOC2LP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOC2LP2 survival associations across molecular data types. NOC2LP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOC2LP2 RNA expression–survival associations across cancer types. High NOC2LP2 expression shows unfavorable associations in KICH, LIHC, COAD, LUSC, DLBC and SARC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for NOC2LP2 RNA expression.
This table summarizes NOC2LP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NOC2LP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOC2LP2 shows higher tumor expression in HNSC, COAD, LUAD, STAD, LUSC and LIHC. The HNSC box plot shows higher NOC2LP2 RNA expression in tumor versus normal tissue (log2 FC = +0.082, t-test p < 0.001).
This table shows molecular features associated with NOC2LP2 in patient tissues and cancer cell lines. In patient samples, NOC2LP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NOC2LP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
